This article is more than 5 years old. Information may no longer be current.

Sentosa genotyping assay detects HIV drug resistance mutations

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

PHILADELPHIA — Gerd Michel, PhD, chief scientific officer for Vela Diagnostics, describes the first next-generation, sequencing-based test able to detect HIV drug resistance mutations. According to data he presented at the American Association for Clinical Chemistry’s Annual Scientific Meeting and Clinical Lab Expo, the Sentosa SQ HIV-1 genotyping assay demonstrated 100% sensitivity to drug resistance mutations in the protease gene, and identified 98.16% of all drug resistance mutations in the reverse transcriptase gene.

Disclosure: Michel is an employee of Vela Diagnostics, manufacturer of the Sentosa SQ HIV-1 genotyping assay.